Last reviewed · How we verify
Intravenous Norepinephrine Bolus
Intravenous Norepinephrine Bolus, developed by Mansoura University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging its mechanism to address critical medical needs. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Intravenous Norepinephrine Bolus |
|---|---|
| Sponsor | Mansoura University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis (PHASE3)
- The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery (PHASE4)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients Undergoing Major Abdominal Procedures - A Pilot Study (NA)
- Hemodynamics During Cesarean Delivery Under Spinal Anesthesia With Norepinephrine Versus Ephedrine (PHASE4)
- Noradrenaline Versus Standard Blood Pressure Management for Perioperative Hypotension in Non-cardiac Surgery (PHASE3)
- Early Intravenous Hydrocortisone in Sepsis (NA)
- Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Norepinephrine Bolus CI brief — competitive landscape report
- Intravenous Norepinephrine Bolus updates RSS · CI watch RSS
- Mansoura University portfolio CI